查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1947944

補體C5重組單株抗體市場按應用、產品類型、最終用戶和研究領域分類－全球預測，2026-2032年

Complement C5 Recombinant Monoclonal Antibody Market by Application, Product Type, End User, Research Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年補體 C5 重組單株抗體市值為 88.6 億美元，預計到 2026 年將成長至 93.7 億美元，到 2032 年將達到 148.1 億美元，複合年成長率為 7.61%。

關鍵市場統計數據
基準年 2025 88.6億美元
預計年份：2026年 93.7億美元
預測年份 2032 148.1億美元
複合年成長率 (%) 7.61%

本書對C5重組單株抗體進行了簡潔且權威的介紹，整合了科學證據、臨床應用和商業性重點。

標靶補體C5的重組單株抗體領域正經歷快速的技術改善和日益複雜的臨床應用，因此，亟需為研發、臨床和商業領域的領導者提供清晰實用的介紹。本文概述了靶向C5生物製劑的核心科學特徵，將其作用機制置於補體通路調控的背景下進行闡述，並解釋了為何選擇性、效應功能調節和可生產性仍然是核心研發重點。

尖端工程技術、適應性臨床設計與製造創新如何重塑C5療法的開發路徑與競爭優勢

該產業正經歷變革性的轉變，重塑著C5標靶藥物的發現、開發和定位方式。抗體工程技術的進步使得補體活性的精確調控成為可能，而Fc沉默設計和同型選擇則降低了脫靶效應並提高了耐受性。同時，高解析度結構生物學和次世代定序技術的進步增強了表位定位和候選藥物篩選，縮短了從先導化合物發現到候選藥物最佳化的迭代週期。

對2025年美國對生物製藥供應鏈和專案韌性徵收關稅的廣泛營運和策略影響評估

近期貿易政策的調整生物製藥（包括C5重組單株抗體）研發和商業化企業的營運成本會計引入了新的變數。關稅措施及相關合規要求正在影響從全球供應鏈採購的原料、一次性耗材和設備的投入成本，促使申辦方和生產商重新評估籌資策略和庫存管理政策。

詳細的細分分析揭示了應用、產品類型、最終用戶和研究領域的差異將如何從根本上改變開發重點和市場進入策略。

細分市場分析揭示了不同領域（臨床、產品、終端用戶和研究領域）的研發和商業化路徑的差異。從應用角度來看，診斷領域強調伴隨診斷和可靠的體外診斷測試對於識別有效患者群體的重要性，而研究性應用則側重於臨床研究以檢驗治療假設，以及臨床前研究以完善作用機制和安全性特徵。這些基於應用領域的差異會影響證據預期、合作夥伴生態系統和轉化里程碑時間表。

全面的區域觀點：說明美洲、歐洲、中東和非洲以及亞太地區如何以獨特的方式影響臨床策略、監管計劃和供應決策。

區域特徵對產品開發、生產製造、監管規劃和商業性合作等方面的策略選擇有顯著影響。美洲地區專注於先進的臨床試驗基礎設施、支付方合作策略以及與診斷生態系統的整合，這為那些能夠提供清晰的患者納入夥伴關係並展現出良好安全性的項目創造了機會。該地區的臨床和學術合作往往能夠加速轉化研究，並有助於快速檢驗生物標記主導的方法。

公司層面的策略趨勢和夥伴關係模式定義了抗體設計、合約服務和診斷合作領域的競爭優勢

成熟的生物製劑研發公司、專業抗體設計公司、合約服務供應商和診斷合作夥伴之間既競爭又合作的動態塑造了C5治療生態系統。領先的生物製藥公司正在投資新一代抗體形式和整合開發路徑，將治療項目與預測性生物標記和診斷策略聯繫起來。專業設計公司提供差異化的平台，例如Fc修飾、半衰期延長和親和性成熟，以加速先導藥物最適化。

為領導者提供切實可行的策略指南，以協調抗體設計、診斷合作和穩健的供應策略，從而加速轉化成功。

行業領導者應採取整合策略，將藥物發現的優先事項與下游開發和商業化需求聯繫起來。首先，應使抗體設計決策與明確的臨床假設保持一致：選擇與預期作用機制和安全性要求相匹配的同型和效應譜，並在正交的體外和體內模型中檢驗這些選擇，以降低轉化過程中的不確定性。其次，應在專案生命週期的早期階段就納入生物標記和診斷策略，以最佳化研究設計，並向監管機構和支付者提供清晰的價值提案。

採用嚴謹透明的混合研究途徑，結合專家訪談、二手證據綜合和情境分析，以獲得切實可行的見解。

本研究採用多模態調查方法，結合專家訪談、文獻綜述和主題分析，以得出可靠的研究結果。主要資訊來源包括對藥物發現、轉化研究、監管事務和生產營運領域的專家進行結構化訪談，以了解實際應用中的限制因素和戰術性策略。二級資訊來源，以闡明與C5抗體研發相關的技術進步、監管先例和臨床設計創新。

整合關鍵的科學、監管和營運要求，這些要求共同決定了C5標靶生物製劑的轉化成功。

總之，靶向補體C5的重組單株抗體的開發，是快速發展的科學、監管預期和實際操作三者相互交織的結果，這些因素共同決定了計畫的可行性。儘管抗體設計和檢測方法開發的進步為提高選擇性和安全性提供了明確的途徑，但成功的轉化研究需要對生物標記、診斷和生產策略進行協調規劃，以應對監管機構和支付方的審查。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 按應用分類的補體C5重組單株抗體市場

  • 診斷
    • 伴隨診斷
    • 用於體外診斷
  • 出於研究目的
    • 臨床研究
    • 臨床前研究
  • 治療用途

9. 補體C5重組單株抗體市場（依產品類型分類）

  • IgG1
  • IgG2
  • IgG3
  • IgG4

第10章 依最終用戶分類的補體C5重組單株抗體市場

  • 學術和研究機構
  • CRO（受託研究機構）
  • 診斷檢查室
  • 製藥和生物技術公司

第11章 依研究領域分類的補體C5重組單株抗體市場

  • 自體免疫疾病
  • 感染疾病
  • 神經系統疾病
  • 腫瘤學

12. 各地區補體C5重組單株抗體市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 補體C5重組單株抗體市場（按組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各國補體C5重組單株抗體市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

15. 美國補體C5重組單株抗體市場

第16章 中國補體C5重組單株抗體市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen Inc.
  • Apellis Pharmaceuticals, Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celltrion Inc.
  • Eli Lilly and Company
  • Horizon Therapeutics plc
  • Janssen Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Roche Holding AG
  • Samsung Bioepis Co., Ltd.
  • Sanofi
  • UCB SA
Product Code: MRR-4F7A6D4FB69A

The Complement C5 Recombinant Monoclonal Antibody Market was valued at USD 8.86 billion in 2025 and is projected to grow to USD 9.37 billion in 2026, with a CAGR of 7.61%, reaching USD 14.81 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.86 billion
Estimated Year [2026] USD 9.37 billion
Forecast Year [2032] USD 14.81 billion
CAGR (%) 7.61%

A concise and authoritative primer on C5 recombinant monoclonal antibodies that aligns scientific rationale with translational and commercial priorities

The landscape for complement C5 recombinant monoclonal antibodies is characterized by rapid technical refinement and increasingly sophisticated clinical applications, demanding a clear, actionable primer for leaders across research, clinical, and commercial functions. This introduction frames the core scientific attributes of C5-targeting biologics, situating their mechanism of action within complement pathway modulation and clarifying why selectivity, effector function tuning, and manufacturability remain central development priorities.

From an R&D perspective, rigorous target validation and assay standardization are essential to translate molecular efficacy into reproducible clinical signals. Concurrently, translational considerations such as biomarker selection, patient stratification strategies, and companion diagnostic alignment are becoming determinative factors in early-phase trial design. These scientific and operational vectors interact with regulatory expectations and payer dialogue, shaping program risks and go-to-market readiness.

This introduction also underscores the interdisciplinary coordination required to advance C5 therapeutics: discovery scientists, process engineers, clinical development teams, and commercial strategists must align on product profiles and evidence generation plans. By clarifying these foundational themes, stakeholders are better positioned to prioritize investments, refine hypotheses, and ensure that subsequent stages of development reflect both biological rationale and pragmatic development constraints.

How cutting-edge engineering, adaptive clinical design, and manufacturing innovations are reshaping development pathways and competitive advantage in C5 therapeutics

The sector is experiencing transformative shifts that reconfigure how C5-targeted agents are discovered, developed, and positioned. Advances in antibody engineering have enabled more precise modulation of complement activity, with Fc-silent formats and isotype selection reducing off-target effects and improving tolerability. At the same time, growth in high-resolution structural biology and next-generation sequencing has enhanced epitope mapping and candidate selection, shortening the iterative cycles between lead identification and candidate optimization.

Clinical trial design is also evolving; adaptive protocols and enriched enrollment based on molecular biomarkers are becoming standard approaches to demonstrate differentiated efficacy with smaller cohorts. Regulatory bodies increasingly expect robust mechanistic evidence and companion diagnostic strategies when benefit-risk profiles hinge on targeted patient populations. Commercially, partnerships between developers and diagnostic providers are more common, reflecting the necessity of aligning therapeutic claims with demonstrable patient selection strategies.

Finally, manufacturing and supply chain innovations are altering deployment timelines. Single-use bioreactors, intensified upstream processes, and improved analytic control strategies are enabling higher quality and consistency at scale. These technological, clinical, and operational inflections collectively create a more dynamic environment where speed, precision, and evidence alignment drive competitive advantage.

Evaluating the broad operational and strategic ramifications of recent United States tariff measures on biologics supply chains and program resilience in 2025

Recent trade policy adjustments have introduced new variables into the operational calculus for organizations that develop and commercialize biologics, including C5 recombinant monoclonal antibodies. Tariff measures and associated compliance requirements influence input costs for raw materials, single-use consumables, and equipment sourced across global supply chains, prompting sponsors and manufacturers to reassess sourcing strategies and inventory policies.

Beyond direct cost implications, tariffs exert indirect pressure by encouraging reconfiguration of manufacturing footprints and supplier relationships. Some organizations respond by onshoring critical stages of production or qualifying alternate vendors in tariff-neutral jurisdictions, while others pursue vertical integration to insulate key processes from cross-border trade volatility. These responses carry implications for capital deployment, timelines for capacity expansion, and regulatory submissions tied to specific manufacturing sites.

Importantly, tariff-related uncertainty also affects contracting and procurement behavior. Procurement teams increasingly build layered contingencies into supplier agreements and seek contractual terms that allocate tariff risk. Investors and partners evaluate program resilience to trade shocks as part of overall program de-risking, influencing strategic decisions around collaboration, licensing, and geographic rollout. In this context, a disciplined approach to supply chain visibility, tariff impact modeling, and scenario planning is essential to preserve program momentum and ensure consistent patient access.

In-depth segmentation insights revealing how application, product type, end-user, and research area distinctions fundamentally alter development priorities and go-to-market tactics

Segmentation analysis reveals how development and commercialization pathways diverge across distinct clinical, product, end-user, and research-area contexts. When considered through the lens of application, diagnostic settings emphasize the necessity of companion diagnostics and robust in vitro assays to identify responsive patient segments, while research use spans clinical research that validates therapeutic hypotheses and preclinical research that refines mechanism and safety profiles. These application-driven distinctions influence evidence expectations, partner ecosystems, and timelines for translational milestones.

Product-type segmentation likewise shapes technical strategy; IgG1 formats are often selected when effector function is desirable or tolerable, whereas IgG2, IgG3, and IgG4 subclasses are chosen to modulate effector interactions or to minimize complement activation, informing engineering decisions related to stability, half-life, and manufacturability. End-user segmentation further differentiates demand signals and support requirements: academic and research institutes prioritize novel tool antibodies and technical support for exploratory studies, contract research organizations focus on validated reagents and scalable protocols to serve client pipelines, diagnostic laboratories seek reproducible performance in regulated environments, and pharmaceutical and biotech companies demand GMP-aligned materials and regulatory documentation for translational progression.

Overlaying these axes is research-area segmentation, which directs therapeutic intent and safety considerations. Projects oriented to autoimmune disorders need durable modulation with careful immunogenicity management, infectious disease work prioritizes rapid neutralization and breadth against pathogen variants, neurological disorder programs must account for blood-brain barrier considerations and long-term tolerability, and oncology-focused efforts integrate complement modulation with immune-oncology strategies. Synthesizing these segmentation perspectives enables teams to prioritize candidate attributes, evidence generation plans, and partner selection aligned to the specific clinical and commercial contexts they target.

Comprehensive regional perspectives explaining how the Americas, Europe Middle East & Africa, and Asia-Pacific uniquely influence clinical strategy, regulatory planning, and supply decisions

Regional dynamics materially influence strategic choices for product development, manufacturing, regulatory planning, and commercial engagement. In the Americas, emphasis on advanced clinical trial infrastructure, payer engagement strategies, and integration with diagnostic ecosystems creates opportunities for programs that can articulate clear patient selection criteria and demonstrate strong safety profiles. Clinical partnerships and academic collaborations in this region often accelerate translational studies and enable rapid validation of biomarker-driven approaches.

Europe, Middle East & Africa presents a heterogeneous regulatory and healthcare landscape where multi-jurisdictional submissions, regional reimbursement pathways, and variable access frameworks necessitate flexible market entry strategies. This region rewards precise evidence packages that account for local clinical practice patterns and health technology assessment requirements, and it encourages cross-border manufacturing strategies that mitigate tariff and logistic complexities.

Asia-Pacific is characterized by a combination of growing clinical research capacity, diverse regulatory environments, and rapidly expanding manufacturing competencies. Local regulatory pathways increasingly align with international standards while offering expedited review mechanisms for high-need therapies. Strategic collaborations with regional contract manufacturers, clinical centers of excellence, and diagnostic partners can reduce time to local proof-of-concept and support scalable supply operations. Taken together, these regional profiles inform prioritization of clinical sites, supply chain architecture, and stakeholder engagement plans to maximize development efficiency and patient access.

Strategic company-level dynamics and partnership models that define competitive advantage across antibody engineering, contract services, and diagnostic collaboration

Competitive and collaborative dynamics among established biologics developers, specialized antibody engineering firms, contract service providers, and diagnostic partners are shaping the C5 therapeutic ecosystem. Leading biopharmaceutical organizations are investing in next-generation antibody formats and integrated development pathways that couple therapeutic programs with predictive biomarkers and diagnostic strategies. Specialized engineering firms contribute differentiated platforms for Fc modification, half-life extension, and affinity maturation that accelerate lead optimization.

Contract research and manufacturing organizations play a pivotal role in enabling program scalability, offering modular process development, analytical method transfer, and GMP-compliant production that support both early clinical supply and later-stage manufacturing transitions. Diagnostic companies and pathology services are increasingly important collaborators for companion diagnostic co-development and for delivering the assays necessary to support enrollment criteria and post-market monitoring.

Partnership models vary from co-development agreements that align incentive structures around shared milestones to service-oriented engagements that provide discrete capabilities such as bioanalytical testing or cell-line development. Across these configurations, successful companies demonstrate discipline in evidence generation, transparent data packages for regulatory review, and clear commercialization pathways that anticipate payer and health system requirements. Ultimately, the ecosystem rewards organizations that couple scientific differentiation with operational excellence and strategic partnership execution.

Actionable strategic directives for leaders to harmonize antibody engineering, diagnostic alignment, and resilient supply strategies to accelerate translational success

Industry leaders should pursue integrated strategies that link discovery priorities with downstream development and commercialization imperatives. First, align antibody engineering decisions with a clear clinical hypothesis: select isotypes and effector profiles that match the intended mechanism and safety requirements, and validate these choices with orthogonal in vitro and in vivo models to reduce translational uncertainty. Second, embed biomarker and diagnostic planning early in the program lifecycle to enable enriched trial designs and clearer value propositions for regulators and payers.

Operationally, diversify supplier bases for critical raw materials and consider qualifying alternative manufacturing sites to reduce exposure to trade policy disruptions. Invest in analytics and digital tools that provide real-time visibility into procurement, lot traceability, and capacity constraints. From a partnership perspective, structure agreements with contract research and manufacturing organizations to allow rapid scale-up while preserving technical oversight and intellectual property safeguards.

Finally, drive stakeholder alignment through cross-functional governance that integrates scientific, regulatory, commercial, and supply chain perspectives. Use phased decision gates with defined data expectations to ensure resource allocation is commensurate with program risk and potential. By implementing these actions, organizations can increase resilience, shorten development timelines, and position programs to meet clinical and market expectations efficiently.

A rigorous and transparent mixed-methods research approach combining expert interviews, secondary evidence synthesis, and scenario-based analysis to derive practical insights

This research employed a multi-modal methodology combining primary expert engagement, secondary literature synthesis, and thematic analysis to produce robust insights. Primary inputs included structured interviews with subject-matter experts across discovery, translational research, regulatory affairs, and manufacturing operations to capture real-world constraints and tactical approaches. Secondary sources were systematically reviewed to contextualize technological advances, regulatory precedents, and clinical design innovations relevant to complement C5 antibody development.

Analytical techniques emphasized cross-validation of qualitative inputs, triangulating interview findings with documented case examples and peer-reviewed science to ensure conclusions reflect replicable phenomena rather than anecdotal observations. Regulatory and supply chain implications were examined through scenario mapping and sensitivity analysis to reveal common risk mitigations and strategic options. The methodology prioritized transparency of assumptions and traceability of evidence to support reproducible decision-making by stakeholders.

Ethical and compliance considerations were integrated throughout the process, ensuring that recommendations respect patient safety priorities, data integrity standards, and international regulatory norms. This methodological approach yields insights that are both actionable and defensible for teams preparing to advance C5-targeted therapeutics from discovery through clinical validation and commercial readiness.

Synthesis of critical scientific, regulatory, and operational imperatives that collectively determine the translational success of C5 targeted biologics

In closing, the development of complement C5 recombinant monoclonal antibodies intersects rapidly evolving science, regulatory expectations, and operational realities that together determine program viability. Technical progress in antibody engineering and assay development offers clear pathways to improved selectivity and safety profiles, yet successful translation requires coordinated planning around biomarkers, diagnostics, and manufacturing strategies that anticipate regulatory and payer scrutiny.

Stakeholders who invest in cross-functional alignment, robust supplier diversification, and early diagnostic co-development will be better positioned to navigate the complex decision points that characterize late preclinical and clinical stages. Additionally, proactive management of trade and supply risks, coupled with adaptive clinical designs, enhances resilience and preserves program momentum in the face of external shocks. The cumulative imperative is clear: disciplined evidence generation, operational adaptability, and strategic partnerships are the cornerstones of sustainable progress in this therapeutic space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Complement C5 Recombinant Monoclonal Antibody Market, by Application

  • 8.1. Diagnostic
    • 8.1.1. Companion Diagnostics
    • 8.1.2. In Vitro Diagnostics
  • 8.2. Research Use
    • 8.2.1. Clinical Research
    • 8.2.2. Preclinical Research
  • 8.3. Therapeutic

9. Complement C5 Recombinant Monoclonal Antibody Market, by Product Type

  • 9.1. IgG1
  • 9.2. IgG2
  • 9.3. IgG3
  • 9.4. IgG4

10. Complement C5 Recombinant Monoclonal Antibody Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Contract Research Organizations
  • 10.3. Diagnostic Laboratories
  • 10.4. Pharmaceutical & Biotech Companies

11. Complement C5 Recombinant Monoclonal Antibody Market, by Research Area

  • 11.1. Autoimmune Disorders
  • 11.2. Infectious Diseases
  • 11.3. Neurological Disorders
  • 11.4. Oncology

12. Complement C5 Recombinant Monoclonal Antibody Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Complement C5 Recombinant Monoclonal Antibody Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Complement C5 Recombinant Monoclonal Antibody Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Complement C5 Recombinant Monoclonal Antibody Market

16. China Complement C5 Recombinant Monoclonal Antibody Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alexion Pharmaceuticals, Inc.
  • 17.7. Amgen Inc.
  • 17.8. Apellis Pharmaceuticals, Inc.
  • 17.9. AstraZeneca PLC
  • 17.10. Biogen Inc.
  • 17.11. Boehringer Ingelheim International GmbH
  • 17.12. Bristol Myers Squibb Company
  • 17.13. Celltrion Inc.
  • 17.14. Eli Lilly and Company
  • 17.15. Horizon Therapeutics plc
  • 17.16. Janssen Pharmaceuticals, Inc.
  • 17.17. Merck & Co., Inc.
  • 17.18. Novartis AG
  • 17.19. Pfizer Inc.
  • 17.20. Regeneron Pharmaceuticals, Inc.
  • 17.21. Roche Holding AG
  • 17.22. Samsung Bioepis Co., Ltd.
  • 17.23. Sanofi
  • 17.24. UCB S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IN VITRO DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRECLINICAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG1, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG2, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG3, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY IGG4, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PHARMACEUTICAL & BIOTECH COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 130. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 132. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 133. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 134. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 151. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 153. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 154. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 158. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 161. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 162. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY DIAGNOSTIC, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH USE, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA COMPLEMENT C5 RECOMBINANT MONOCLONAL ANTIBODY MARKET SIZE, BY RESEARCH AREA, 2018-2032 (USD MILLION)